Examkin

Soru

Zorluk: Çok zorPreventive Care and Screening

A 54-year-old female presents for a comprehensive wellness examination. Her past medical history is significant for HIV (diagnosed 10 years ago) and seropositive rheumatoid arthritis. Her HIV is well-controlled on a daily antiretroviral regimen; her most recent CD4 count is 450 cells/mm³ and her viral load is undetectable. Her rheumatoid arthritis is managed with methotrexate and adalimumab. She also has asthma, managed with an inhaled corticosteroid.

Her surgical history is notable for a radical hysterectomy with pelvic lymph node dissection and bilateral salpingo-oophorectomy performed at age 42 for stage IB cervical cancer.

Social history reveals she smoked one pack of cigarettes daily from age 20 to 35 (15 pack-years) but quit 19 years ago.

Preventive care history:
- Screening mammogram at age 52 was reported as BI-RADS 2 (benign findings).
- Screening colonoscopy at age 45 was completely normal.
- She is up to date on her annual influenza vaccination, COVID-19 vaccination, and received a Tdap booster 2 years ago.
- She has never received any pneumococcal vaccinations.
- Her fasting lipid panel and hemoglobin A1c, obtained last week, are within normal limits.

She has no acute symptoms and feels well today. Which of the following is the most appropriate next step in the preventive care of this patient?

  1. A
    Advise the patient that she no longer requires routine lower genital tract cancer screening
  2. Administer the 20-valent pneumococcal conjugate vaccine (PCV20)Cevap
  3. C
    Schedule a screening colonoscopy to be performed within the next month
  4. D
    Order a low-dose chest computed tomography (LDCT) for lung cancer screening
  5. E
    Check measles, mumps, and rubella (MMR) titers and administer the MMR vaccine if negative

Cevap

Administer the 20-valent pneumococcal conjugate vaccine (PCV20)
The correct intervention is to administer the 20-valent pneumococcal conjugate vaccine (PCV20). According to the Advisory Committee on Immunization Practices (ACIP), adults aged 19 to 64 years with certain underlying medical conditions—including immunocompromising conditions like HIV infection and iatrogenic immunosuppression from biologic agents (e.g., adalimumab)—who have not previously received a pneumococcal vaccine should receive a single dose of PCV20 (or alternatively, a dose of PCV15 followed by PPSV23). Because this patient is vaccine-naïve and has multiple qualifying immunocompromising conditions, she requires this vaccination immediately.

Adım Adım Çözüm

1
Evaluate the patient's immune status and vaccination requirements.
The patient is severely immunocompromised due to both HIV infection and active treatment with adalimumab (a TNF inhibitor). She is also pneumococcal vaccine-naïve.
ACIP guidelines dictate specific accelerated and expanded pneumococcal schedules for adults aged 19 to 64 years with altered immunocompetence.
2
Assess the indication for lower genital tract screening given her surgical history.
The patient must continue to undergo vaginal cuff cytology screening.
Although she had a total hysterectomy, it was performed for cervical cancer. The ASCCP guidelines require continuous screening for at least 25 years following treatment for CIN2, CIN3, or cervical cancer.
3
Review her eligibility for lung cancer screening.
She is ineligible for LDCT screening.
Current USPSTF guidelines require a minimum 20 pack-year smoking history and for the patient to be a current smoker or have quit within the past 15 years. Her 15 pack-year history and 19-year cessation duration exclude her.
4
Check for contraindications to live vaccines.
Live vaccines (e.g., MMR) are strictly contraindicated.
While an HIV patient with a CD4 count >200 cells/mm³ can generally receive the MMR vaccine, concurrent therapy with a biologic immunosuppressant (adalimumab) serves as an absolute contraindication to all live-attenuated vaccines.

Anahtar Kavram

Adults aged 19-64 with immunocompromising conditions should receive the PCV20 vaccine. Furthermore, preventive screening intervals and contraindications must be strictly tailored to specific surgical histories and pharmacologic therapies.
Tahmini Süre:1m 30s
Bu soruyu puanla

Konular

Preventive Care and Screening

Bu konudan daha fazla soru